Subscribe
Subscribe
MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
Logo IMG
HOME > MULTIMEDIA > Multimedia Detail

SCIENCE IN THE NEWS DAILY

Promising Alzheimer's Drug Approved for Late-Stage Trials

from USA Today

An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.

Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.

In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.

Read more ...


comments powered by Disqus
 

Connect With Us:

                   

Latest Multimedia

Audio: Using Computing to Advance Toxicology

Chemicals have changed our lives, providing new products and capabilities, but sometimes causing harm to ourselves and the environment... (click the link above to read more).

To view all multimedia content, click "Latest Multimedia."


RSS Feed Subscription

Receive notification when new content is posted from the entire website, or choose from the customized feeds available.


EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Three Doctors Charged in Armstrong Doping Case

Science In The News Daily: Fish Oil Fail: Omega-3s May Not Protect Brain Health After All

Science In The News Daily: Antibody Cocktail Cures Monkeys of Ebola

Subscribe to American Scientist